Payment overview · 2025
General Payments
$952.32
43 reported records · 8 companies
Healthcare provider profile · identity verified
Thaddeus G Sutton, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HAMPTON, VA · NPI 1558321349
Verified facts
What the public records show
CMS Open Payments records show Thaddeus G Sutton, MD received $952.32 in general payments during 2025 across 43 reported records.
Amgen Inc. accounted for 35.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $333.61 | 35.0% | 17 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $220.44 | 23.1% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $100.62 | 10.6% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $93.10 | 9.8% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $92.25 | 9.7% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.54 | 5.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.52 | 3.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.24 | 3.1% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $952.32 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $255.64 | 12 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $220.44 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $121.52 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $100.62 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $77.97 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $59.35 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $57.33 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $56.90 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $51.90 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $51.18 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $47.54 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.33 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.16 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.24 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 51 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
62 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 914 | 266 |
| Atorvastatin Calcium | Atorvastatin Calcium | 692 | 193 |
| Hydrochlorothiazide | Hydrochlorothiazide | 381 | 104 |
| Furosemide | Furosemide | 337 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 328 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 326 | 101 |
| Potassium Chloride | Potassium Chloride | 319 | 97 |
| Losartan Potassium | Losartan Potassium | 296 | 85 |
| Omeprazole | Omeprazole | 286 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 253 | 76 |
| Simvastatin | Simvastatin | 244 | 64 |
| Metformin Hcl | Metformin Hcl | 219 | 58 |
| Carvedilol | Carvedilol | 215 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 214 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 196 | 56 |
| Metformin Hcl Er | Metformin Hcl | 188 | 59 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 172 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 167 | 42 |
| Gabapentin | Gabapentin | 164 | 52 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 145 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 139 | 47 |
| Glimepiride | Glimepiride | 135 | 45 |
| Lisinopril | Lisinopril | 134 | 44 |
| Allopurinol | Allopurinol | 129 | 37 |
| Clonidine Hcl | Clonidine Hcl | 127 | 31 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 120 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 103 | 28 |
| Glipizide | Glipizide | 96 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 96 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 26 |
| Meloxicam | Meloxicam | 92 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 91 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 90 | 38 |
| Januvia | Sitagliptin Phosphate | 87 | 21 |
| Prednisone | Prednisone | 87 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 30 |
| Spironolactone | Spironolactone | 82 | 27 |
| Ibuprofen | Ibuprofen | 80 | 27 |
| Glipizide Er | Glipizide | 79 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 26 |
| Cetirizine Hcl | Cetirizine Hcl | 76 | 27 |
| Eliquis | Apixaban | 76 | 23 |
| Montelukast Sodium | Montelukast Sodium | 73 | 23 |
| Meclizine Hcl | Meclizine Hcl | 72 | 27 |
| Nebivolol Hcl | Nebivolol Hcl | 68 | 15 |
| Methocarbamol | Methocarbamol | 65 | 24 |
| Azithromycin | Azithromycin | 62 | 51 |
| Synthroid | Levothyroxine Sodium | 62 | 18 |
| Colchicine | Colchicine | 60 | 25 |
| Verapamil Er | Verapamil Hcl | 60 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 57 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 14 |
| Chlorthalidone | Chlorthalidone | 56 | 17 |
| Atenolol | Atenolol | 55 | 12 |
| Trazodone Hcl | Trazodone Hcl | 54 | 19 |
| Alendronate Sodium | Alendronate Sodium | 53 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 53 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 15 |
| Ozempic | Semaglutide | 53 | suppressed |
| Telmisartan | Telmisartan | 53 | 14 |
| Jardiance | Empagliflozin | 51 | 20 |
| Mupirocin | Mupirocin | 49 | 27 |
| Celecoxib | Celecoxib | 48 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 48 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 48 | 18 |
| Warfarin Sodium | Warfarin Sodium | 48 | suppressed |
| Alprazolam | Alprazolam | 47 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 47 | suppressed |
| Pregabalin | Pregabalin | 47 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 38 |
| Levetiracetam | Levetiracetam | 46 | 13 |
| Diazepam | Diazepam | 45 | suppressed |
| Ezetimibe | Ezetimibe | 45 | 19 |
| Famotidine | Famotidine | 45 | 12 |
| Tramadol Hcl | Tramadol Hcl | 45 | 11 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 45 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 16 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 42 | 13 |
| Amoxicillin | Amoxicillin | 41 | 32 |
| Tradjenta | Linagliptin | 41 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 40 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 39 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 38 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 38 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | 13 |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Naproxen | Naproxen | 31 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 30 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 30 | 11 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Clarithromycin | Clarithromycin | 27 | 18 |
| Fluconazole | Fluconazole | 27 | 16 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 19 |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Lactulose | Lactulose | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | 15 |
| Nystatin | Nystatin | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Acetic Acid | Acetic Acid | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $952.32 · 43 records | Amgen Inc. | ACCRUFER, AIRSUPRA, EVENITY, JARDIANCE, KISUNLA, MOUNJARO, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error